Search
EHA-ECL led statement calls for protection of the Hospital Exemption
The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.
Read moreEHA policy on double awarding
EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.
Read moreEHA Research Conference 2024
Dates: March 18-21, 2024
Location: Borovets, Bulgaria
Chairs: Anna Kabanova, Martina Muckenthaler, Andreas Trumpp, Simon Haas, Jean-Emmanuel Sarry, Achille Iolascon, Britta Will and Brian Huntly
Registration is closed
EHA is proud to announce the second edition of the EHA Research Conference, titled "Molecular vulnerabilities and…
From bedside to Brussels: hematology at the forefront of EU health policy
Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.
Read moreMedia
How to register for the EHA2025 Congress as a member of the press. Online press registration for EHA2025 will be open until 23:59 (CEST) on June 11, 2025.
Read morePromising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013
What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.
Read more